APM
CRSP icon

Avidity Partners Management’s CRISPR Therapeutics CRSP Stock Holding History

Avidity Partners Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-274,300
Closed -$20.2M – 74
2020
Q2 		$20.2M Buy
+274,300
New +$16M 1.29% 30

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Avidity Partners Management's CRSP Position: Q3 2020 in Review

Avidity Partners Management sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 274,300 shares — an estimated $20.2M sold.

Avidity Partners Management first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $20.2M in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Avidity Partners Management reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Avidity Partners Management sold 274,300 CRISPR Therapeutics shares in Q3 2020, an estimated $20.2M.
  • Avidity Partners Management first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Avidity Partners Management's CRISPR Therapeutics position peaked at $20.2M in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.